The effects of other GLP-1 RAs on cardiovascular outcomes remain to be evaluated in patients with obesity or overweight, however, the results of the SELECT trial highlight the importance of treating obesity to reduce cardiovascular risk [33]. The gene discussed is GCG; the disease is obesity disorder.